EP0553273A4 - Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging - Google Patents

Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging

Info

Publication number
EP0553273A4
EP0553273A4 EP91920236A EP91920236A EP0553273A4 EP 0553273 A4 EP0553273 A4 EP 0553273A4 EP 91920236 A EP91920236 A EP 91920236A EP 91920236 A EP91920236 A EP 91920236A EP 0553273 A4 EP0553273 A4 EP 0553273A4
Authority
EP
European Patent Office
Prior art keywords
deferoxamine
polymer
magnetic resonance
resonance imaging
ferric iron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP91920236A
Other versions
EP0553273A1 (en
Inventor
Bo E Hedlund
Phillip E Hallaway
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Frontiers Inc
Original Assignee
Biomedical Frontiers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Frontiers Inc filed Critical Biomedical Frontiers Inc
Publication of EP0553273A1 publication Critical patent/EP0553273A1/en
Publication of EP0553273A4 publication Critical patent/EP0553273A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Signal Processing (AREA)
  • Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP91920236A 1990-10-16 1991-10-15 Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging Withdrawn EP0553273A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59804490A 1990-10-16 1990-10-16
US598044 1990-10-16

Publications (2)

Publication Number Publication Date
EP0553273A1 EP0553273A1 (en) 1993-08-04
EP0553273A4 true EP0553273A4 (en) 1998-04-22

Family

ID=24393999

Family Applications (1)

Application Number Title Priority Date Filing Date
EP91920236A Withdrawn EP0553273A4 (en) 1990-10-16 1991-10-15 Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging

Country Status (5)

Country Link
EP (1) EP0553273A4 (en)
JP (1) JPH06502177A (en)
AU (1) AU8950291A (en)
CA (1) CA2094028A1 (en)
WO (1) WO1992007259A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
CA2128031A1 (en) * 1992-01-15 1993-07-22 Michael K. Brawer A method for estimating the biologic potential of a selected carcinoma in a patient
US5494030A (en) * 1993-08-12 1996-02-27 Trustees Of Dartmouth College Apparatus and methodology for determining oxygen in biological systems
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
AT409929B (en) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Infusion solution containing inert macromolecule becoming preferentially enriched in tumor-associated neovascularization regions, useful as carrier and targeting agent in tumor diagnosis and therapy
DE19808079A1 (en) * 1998-02-20 1999-08-26 Schering Ag New hydroxyethyl starch conjugates useful as X-ray, NMR and blood-pool diagnostic agents, e.g. for diagnosis of tumors, cardiovascular disorders and inflammation
IL127621A (en) * 1998-12-17 2002-05-23 Yissum Res Dev Co Method for measuring non-bound metal in serum and biological fluids
EP1404334A4 (en) * 2001-05-15 2005-02-02 Faulk Pharmaceuticals Inc Targeted delivery of bioaffecting compounds for the treatment of cancer
US6961607B2 (en) 2002-07-31 2005-11-01 Uzgiris Egidijus E Method for assessing myocardial angiogenesis
US20040024317A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for assessing capillary permeability
KR20050095826A (en) * 2002-12-09 2005-10-04 아메리칸 바이오사이언스, 인크. Compositions and methods of delivery of pharmacological agents
EP2359859A1 (en) 2002-12-09 2011-08-24 Abraxis BioScience, LLC Compositions comprising albumin nanoparticles and methods of delivery of pharmacological agents
CN114460163B (en) * 2022-02-11 2023-03-03 河北师范大学 MALDI mass spectrometry imaging method for detecting iron content of biological tissue

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035765A2 (en) * 1980-03-08 1981-09-16 Nihon Medi-Physics Co., Ltd. A physiologically active substance-combined compound and its use for the preparation of a radioactive metallic element-labeled compound
EP0111311A2 (en) * 1982-12-08 1984-06-20 Nihon Medi-Physics Co., Ltd. Non-radioactive carriers and radioactive diagnostic agent
EP0304183A1 (en) * 1987-08-20 1989-02-22 Biomedical Frontiers, Inc. Stabilization of deferoxamine to chelate free ions in physiological fluid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
US4999445A (en) * 1988-06-10 1991-03-12 The Regents Of The University Of California Contrast agents for magnetic resonance imaging of the small intestine and hepatobiliary system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0035765A2 (en) * 1980-03-08 1981-09-16 Nihon Medi-Physics Co., Ltd. A physiologically active substance-combined compound and its use for the preparation of a radioactive metallic element-labeled compound
EP0111311A2 (en) * 1982-12-08 1984-06-20 Nihon Medi-Physics Co., Ltd. Non-radioactive carriers and radioactive diagnostic agent
EP0304183A1 (en) * 1987-08-20 1989-02-22 Biomedical Frontiers, Inc. Stabilization of deferoxamine to chelate free ions in physiological fluid

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DUEWELL S ET AL: "NONIONIC POLYETHYLENE GLYCOL-FERRIOXAMINE AS A RENAL MAGNETIC RESONANCE CONTRAST AGENT", INVESTIGATIVE RADIOLOGY, vol. 26, no. 1, 1 January 1991 (1991-01-01), pages 50 - 57, XP000576799 *
HALLAWAY PE ET AL: "Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.", PROC NATL ACAD SCI U S A, DEC 1989, VOL. 86, NO. 24, PAGES 10108-12, XP002054495 *
HEDLUND, BO E. ET AL: "High molecular weight forms of deferoxamine: novel therapeutic agents for treatment of iron-mediated tissue injury", ADV. EXP. MED. BIOL., 1990, VOL. 264, NO. ANTIOXID. THER. PREV. MED., PAGES 229-34, XP002054496 *
KOJIMA, SHUJI ET AL: "Comparisons of labeling efficiency, biological activity and biodistribution among indium-125-, gallium-67-DTPA-, and gallium-67-DFO-lectins", EUR. J. NUCL. MED., 1987, VOL. 13, NO. 7, PAGES 366-70, XP002054498 *
LESNEFSKY EJ ET AL: "High-dose iron-chelator therapy during reperfusion with deferoxamine-hydroxyethyl starch conjugate fails to reduce canine infarct size.", J CARDIOVASC PHARMACOL, OCT 1990, VOL. 16, NO. 4, PAGE(S) 523-8, XP002054497 *
MARUYAMA M ET AL: "Effects of hydroxyethyl starch conjugated deferoxamine on myocardial functional recovery following coronary occlusion and reperfusion in dogs.", J CARDIOVASC PHARMACOL, JAN 1991, VOL. 17, NO. 1, PAGE(S) 166-75, XP002054499 *
NAGAMACHI S ET AL: "GALLIUM-67 SCINTIGRAPHY IN PATIENTS WITH HEMOCHROMATOSIS TREATED BY DEFEROXAMINE", ANNALS OF NUCLEAR MEDICINE, vol. 2, no. 1, 1988, pages 35 - 39, XP000653965 *
RONGVED P ET AL: "WATER-SOLUBLE POLYSACCHARIDES AS CARRIERS OF PARAMAGNETIC CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING: SYNTHESIS AND RELAXATION PROPERTIES", CARBOHYDRATE RESEARCH, vol. 214, no. 2, 30 July 1991 (1991-07-30), pages 315 - 323, XP000217853 *
SCHULTHESS VON G K ET AL: "POLYETHYLENE-GLYCOL-FERRIOXAMINE A NEW MAGNETIC RESONANCE CONTRAST AGENT", INVESTIGATIVE RADIOLOGY, vol. 25, no. SUPPL. 01, 1 September 1990 (1990-09-01), pages S48, XP000576801 *
See also references of WO9207259A1 *

Also Published As

Publication number Publication date
JPH06502177A (en) 1994-03-10
WO1992007259A1 (en) 1992-04-30
AU8950291A (en) 1992-05-20
EP0553273A1 (en) 1993-08-04
CA2094028A1 (en) 1992-04-17

Similar Documents

Publication Publication Date Title
EP0412695A3 (en) Magnetic resonance imaging
EP0465068A3 (en) Switched field magnetic resonance imaging
EP0443677A3 (en) Quadrature surface coil construction for magnetic resonance imaging apparatus
GB2245364B (en) Magnetic resonance imaging coil
EP0553273A4 (en) Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging
EP0450949A3 (en) Actively shielded magnetic resonance magnet without cryogens
EP0495287A3 (en) Magnetic resonance imaging
GB8813425D0 (en) Magnetic resonance imaging
GB2240628B (en) Magnetic resonance imaging apparatus
EP0453102A3 (en) Magnetic resonance imaging methods and apparatus
SG49633A1 (en) Magnetic resonance imaging apparatus
GB2234594B (en) Nuclear magnetic resonance imaging methods
GB2252245B (en) Improvements in and relating to magnetic resonance imaging
EP0430104A3 (en) Magnetic resonance imaging apparatus
EP0439119A3 (en) Magnetic resonance imaging system
GB9007655D0 (en) Magnetic resonance imaging technique
GB2245992B (en) Magnetic resonance imaging sequencer gating
GB9600147D0 (en) Gradient coils in magnetic resonance imaging machines
GB2234595B (en) Nuclear magnetic resonance imaging methods
GB2252244B (en) Improvements in and relating to magnetic resonance imaging
GB9105693D0 (en) Nuclear magnetic resonance apparatus
GB2294771B (en) Improvements in or relating to nuclear magnetic resonance (nmr)imaging
EP0467467A3 (en) Nuclear magnetic resonance spectroscopy procedure
GB2279755B (en) Improvements in and relating to magnetic resonance imaging
GB9016391D0 (en) Magnetic resonance imaging

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980309

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE DK FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000503